![]() More than 1379 patients were studied in 2 major clinical trials, where dupilumab was tested against a placebo. How Did the FDA Decide to Approve Dupilumab? ![]() It is also FDA approved for asthma, which is commonly found in association with eczema. It is currently US Food and Drug Administration (FDA) approved for eczema that is inadequately controlled by topical treatments in adults and children ages 6 months or older. It is administered via a subcutaneous injection using a pen or syringe every other week. These medications are specifically designed to target the primary culprits in the inflammatory response responsible for eczema.ĭupilumab (Dupixent) is a biologic that helps block the source of inflammation in eczema. Recent advances in medical treatments for eczema have introduced promising systemic agents such as dupilumab (Dupixent), tralokinumab (Adbry), and abrocitinib (Cibinqo). A diverse array of systemic agents are available for treating eczema, ranging from short-term remedies that provide relief for acute flares (eg, oral steroids, cyclosporine) to long-term maintenance therapies. They are typically recommended when eczema persists despite the use of topical treatments and/or phototherapy, or when the condition significantly affects an individual’s daily activities and overall well-being, particularly when persistent itching interferes with sleep. Systemic agents are a class of medical treatments that work systemwide in the body and are typically given orally or as a subcutaneous injection (an injection under the skin) in the dermatologic setting. What Is a Systemic Agent, and When Are They Used for Eczema? Additionally, prolonged exposure to specific light therapies has been associated with an increased risk of skin cancers, which restricts its use as a long-term maintenance therapy for eczema. ![]() Light therapy can be demanding, though, as it often requires multiple doctor’s office visits every week, which can be inconvenient for many people. Phototherapy, commonly referred to as light therapy, is often considered for those who have not responded to topical agents. This article will explore a diverse range of medical treatments for eczema, focusing on the latest systemic treatments.įirst-line treatments for eczema include topical anti-inflammatory agents (eg, topical corticosteroids and topical calcineurin inhibitors). Fortunately, in recent years, new therapies have emerged that hold great potential for effectively managing eczema. Novel Systemic Agents for Atopic DermatitisĪtopic dermatitis, more commonly known as eczema, is a chronic skin condition that can significantly diminish one’s quality of life, primarily due to the debilitating itch it produces. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |